Company / PP&E (Net)
Inhibrx Biosciences, Inc. PP&E (Net) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.7M
FY2025
5-year range
$3.7M / $6.4M
FY2023-FY2025
Trend
-39.8%
vs FY2024
Sector context
#118 of 193
Health Care
What the data says
At $4M, Inhibrx Biosciences, Inc.'s pp&e (net) ranks #118 of 193 in the Health Care sector. Declined from $6M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2025.
Declined from $6M to $4M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 193 in Health CareTop 61% of 193This company $3.7M Sector average $777.6M
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2025, pp&e (net) decreased 39.8% year-over-year.
- Ranks #118 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.7M | -39.8% |
| FY2024 | $6.2M | -3.4% |
| FY2023 | $6.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026